Despite a shaky quarter due to U.S.-China trade tensions and a 6% dip in stock price, Boston Scientific still flexed its ...

Boston Scientific (NYSE:BSX) experienced a 6% decline in stock price over the last quarter, amid a period of market uncertainty driven by new tariffs imposed by the U.S. and retaliatory measures from ...

Cartesian Therapeutics Inc. followed up December’s phase IIb data with more good news regarding Descartes-08, offering 12-month efficacy and safety results that whetted Wall Street’s appetite for the ...

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance cardiac cryoablation system in treating ...

Atrial tachyarrhythmia recurred in 39 patients treated with Boston Scientific’s Farapulse PFA device, while 53 people had recurrence in the Medtronic cryoablation group.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

With PFA becoming physicians’ preferred ablation method for treating AFib, Abbott is pushing to catch up with rival systems ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

Though late to the party compared to other industry leaders, Abbott joins a pulsed field ablation market poised for significant growth.